(Q33480908)

27 July 2017

Amrinone in the treatment of chronic cardiac failure (English)

1 reference

27 July 2017

Likoff MJ

1

1 reference

27 July 2017

Weber KT

2

1 reference

27 July 2017

Andrews V

3

1 reference

27 July 2017

Janicki JS

4

1 reference

27 July 2017

Sutton MS

5

1 reference

27 July 2017

Wilson H

6

1 reference

27 July 2017

Rocci ML Jr

7

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 May 1984

1 reference

Journal of the American College of Cardiology

27 July 2017

1 reference

27 July 2017

3

1 reference

27 July 2017

5

1 reference

27 July 2017

1282-1290

1 reference

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

The role of vasodilator therapy in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Amrinone and exercise performance in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Oral bioavailability and intravenous pharmacokinetics of amrinone in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Some statistical methods useful in circulation research.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

The epidemiology of cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Vasodilator therapy of cardiac failure: (first of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

New hope for the failing heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

A Clinical Trial Design Avoiding Undue Placebo Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Hemodynamic effects of nitroglycerin in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Influence of short-term oral hydralazine therapy on exercise hemodynamics in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Oral amrinone in refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980189-8

7 January 2021

10.1016/S0735-1097(84)80189-8

Identifiers

DOI

1 reference

27 July 2017

1 reference